Online inquiry

IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13544MR)

This product GTTS-WQ13544MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MCAM gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_006500.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4162
UniProt ID P43121
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13544MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7228MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ7451MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ14965MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ5108MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ3486MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ4099MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ1265MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-414
GTTS-WQ14737MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW